Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 15/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021314 | 1.00 | CYP2D6 (0.41) | CYP2D6CXCR4HDAC1HDAC6CYP3A4 | |
| SCHEMBL5021313 | 1.00 | CYP2D6 (0.41) | CYP2D6CXCR4HDAC1HDAC6CYP3A4 | |
| SCHEMBL5021308 | 0.90 | OPRL1 (0.35) | CYP2D6CXCR4CYP3A4 | |
| SCHEMBL5021309 | 0.90 | OPRL1 (0.35) | CYP2D6CXCR4CYP3A4 | |
| SCHEMBL5021310 | 0.90 | OPRL1 (0.35) | CYP2D6CXCR4CYP3A4 | |
| SCHEMBL18628746 | 0.80 | CXCR4 (0.41) | CYP2D6CXCR4HDAC1HDAC6CYP3A4 | |
| SCHEMBL12891525 | 0.77 | CYP2D6 (0.43) | CYP2D6CXCR4HDAC1HDAC6 | |
| SCHEMBL12891529 | 0.77 | CYP2D6 (0.43) | CYP2D6CXCR4HDAC1HDAC6 | |
| SCHEMBL12092558 | 0.77 | CYP2D6 (0.43) | CYP2D6CXCR4HDAC1HDAC6 | |
| SCHEMBL24804097 | 0.74 | HDAC1 (0.41) | CYP2D6CXCR4HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, CNR1, CNR2 | CYP2D6 1250/4885CXCR4 392/4885HDAC1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.